

M3, Inc.

Presentation Material

October 2020



The following presentation contains forecasts, future plans, management targets and other forward-looking projections relating to M3, Inc. and/or its group. These statements are drawn from assumptions of future events based on data currently available to us, and there exist possibilities that such assumptions are objectively incorrect and/or may produce differing actual results from those mentioned in the statements.

Furthermore, information and data other than those concerning the Company and its subsidiaries/affiliates are quoted from public information, and the Company has not verified and will not warrant its accuracy or dependency.

M3, Inc.

FY2020 Q2 Consolidated Results Summary

FY2020 Q2 Consolidated Results

IFRS

(mn yen)	FY2019 Q2	FY2020 Q2	YoY
Sales	61,545	75,022	+22%
Operating Profit	16,549	23,931	+45%
Pre-tax Profit	16,597	23,943	+44%
Net Profit	11,312	16,587	+47%

+61%
growth
excluding
impacts
such as
stock
sales and
valuation
changes


 Profits increased 41% in Q1, and 83% in Q2 versus previous year, excluding impacts such as asset sales and valuation changes

FY2020 Q2 Consolidated Results by Segment

(mn yen)			FY2019 Q2	FY2020 Q2	YoY	
Domestic	Medical Platform	Sales	22,269	30,915	+39%	+106% YoY profit growth excluding impact such as stock sales
		Profit	7,404	13,748	+86%	
	Evidence Solution	Sales	10,739	9,603	-11%	Temporary demand decrease due to COVID-19
		Profit	2,209	1,631	-26%	
	Career Solution	Sales	8,760	8,194	-6%	Rapid recovery from COVID-19 negative impact
		Profit	3,150	2,824	-10%	
	Site Solution	Sales	5,634	7,976	+42%	Acceleration in yoy profit growth: Q1: +53% Q2: +125%
		Profit	357	829	+132%	
	Emerging Market Businesses	Sales	1,506	1,430	-5%	
		Profit	544	340	-38%	
Overseas		Sales	13,977	18,314	+31%	
		Profit	2,667	5,083	+91%	

FY2020 Q2 Consolidated Operating Profit Contribution Breakdown

(mn yen)



FY2020 Q2 Overview

COVID-19 Impact

Medical Platform

- Accelerated digital transformation in pharma marketing
- Marketing service orders grew 2.5x yoy in H1

+ +

Evidence Solution

- Orders backlog remained steady at 23.5 bn yen despite partial halts in projects

—

Career Solution

- Dampened demand from both physician and pharmacists due to COVID-19

—

Site Solution

- Increase in affiliate sites; COVID-19 related projects boosting rapid recovery

+

Emerging Businesses

- New business seeds being planted at a healthy pace

Neutral


Overseas

- Doubled segment profits due to rapid APAC expansion such as in China
- US clinical trial business recovery, and overall business improvement


+ +

COVID-19 Impact on M3

COVID-19 Impact on M3



COVID-19 Impact on M3



m3.com Site Access Increase

COVID-19 Related Information Provision



Focused delivery of related news




Proactive information exchange across PtoP communities




Expert webinars regarding COVID-19 examination


m3.com Access Increase (% yoy)



m3.com site access remains high after rapid rise since COVID-19; becoming an imperative infrastructure for the medical industry


COVID-19 Impact on M3





 **80~90% of hospitals continue self-restriction requests towards MR visitations**

Marketing Support Service Orders



- Rapid demand increase from pharmaceutical companies due to COVID-19
- Sales team fortification (+78% yoy including external resource utilization) contributing to larger projects
- Fortification of project execution staff yet to be procured

 Pharma companies' shift into full scale DX accelerated demand to exceed that of Q1

- Over 7.8 million “friends” (since launch in Dec 2019)
- Reimbursable online consultation service “LINE Doctor” scheduled for launch in November

LINE、オンライン診療サービスを今夏リリース
LINE Pay連携や予約機能も検討 「医療格差を是正する」

© 2020年05月29日 12時00分 公開 [西川大貴, ITmedia]

印刷 88 Share B! 4

LINEヘルスケアは5月28日、今夏をめどにオンライン診療サービスに参入すると発表し、ビデオ通話や電子決済の導入を計画している。

オンライン診療
LINEに続け

医師が患者とビデオ通話で診療を行う様子。LINEのヘルスケアアプリ「LINE Doctor」が、オンライン診療のプラットフォームとして、医師と患者をつなぐ。

システム会社や医師派遣会社 新聞社が参入

賛否両論のオンライン診療 LINEも参入、医療制度持続への突破口にも

2020年6月18日（木）14時00分

LINEが参入するオンライン診療の現状と、医療制度の持続可能性への影響について、専門家による議論が行われた。

LINE、オンライン診療アプリ参入 8000万顧客生かすー【イブニングスクープ】
2020/05/21 05:20 日本経済新聞電子版 643文字

LINEは今夏にもオンライン診療事業に参入する。ビデオ通話機能を使い、医師が患者を遠隔で診断できる専用のアプリを立ち上げる。国内8千万人超の利用者を抱えるSNS（交流サイト）を生かし、2千人以上の医師の利用を見込む。病院や薬局への支払いを電子決済する仕組み作りも検討。オンライン診療は新型コロナウイルスの感染拡大で需要が高まっている。政府も規制を緩和する中、大きな顧客基盤を持つLINEの動きは普及を後押ししそうだ。

ビデオ通話のほか、同社の電子決済「ラインペイ」をオンライン診療アプリと連動させる。病院や薬局の多くはまだ電子決済に対応していないが、同社は各施設に導入を呼びかけていく。

LINEは診療アプリのサービス料を利用者から徴収する。医師や病院から月額料金をとるか、患者が払うかの形にする。オンライン診療は日本では新興企業が多く、利用料金は医師が支払う場合は数万円、患者負担の場合は1回数百円のケースが多い。資本力のあるLINEの参入によってこうした料金の引き下げが進む可能性がある。

オンライン診療は公的医療保険の対象だ。新型コロナを機に政府が規制緩和し、4月から初診を含めて特例で利用できるようになった。ただ、患者と医療機関の双方が同じサービスを使う必要があり、機器導入に費用や手間がかかることが普及の妨げになっていた。LINEは対話アプリで国内8千万人超の利用者がいる。なじみのあるサービスを入り口にすることで、患者や医師の心理的なハードルを下げて利用を広げたい構えだ。

オンライン診療急拡大、1万5000施設に LINEも参入
2020/06/10 02:00 日本経済新聞電子版 2650文字

病院へ足を運ばなくてもスマートフォンで医師の診察を受けられる「オンライン診療」が急速に広がってきた。これまでは規制が厳しかったため消極的な医師が多かったが、新型コロナウイルスの感染拡大が状況を一変させた。規制緩和もあり、導入する医療機関が急増。LINEなど大手も参入し、医療機器やサービスとの連携も始まった。一方で「医療の質が低下しないか」と懸念する声もある。

■「リラックスして受診できる」
「オンラインは本当に助かる」と患者さんたちに好評だ。都内で内科系クリニックを営む医師の山下氏は、4年前に導入したオンライン診療がコロナ禍で真価を発揮したと語る。利用した都内在住の50代男性は「待ち時間がなく便利。自宅でリラックスして受診でき、質問もしやすい」と効果を話す。


コロナの被害が広がった3月以降、感染を恐れて医療機関に行くのを控えた人は多い。オンライン診療システムのインテグリティ・ヘルスケア（東京・中央）の武藤真祐会長は「外来患者が激減した。診療所を閉鎖するところも増えた。緊急事態宣言は解除

“LINE Doctor” Adoption Intent

Telemedicine




Of doctors that plan to offer online consultations,
83% wish to use “LINE Doctor”



Launch of AI Platform Business

AI




- **Business alliance with NOBORI providing medical cloud services**
- **Connectivity with any PACS (medical image management system)**
- **Multiple AI image diagnostic algorithms will be on-boarded and categorized by physical regions (head, lungs, heart, etc.)**

 **Expanded free provision of COVID-19 pneumonia AI and remote diagnosis services to 121 medical sites across Japan**


**Pulmonary
nodule shadow**

VUNO Med®-LungCT
by 




**Pulmonary
nodules**

EIRL Chest nodule
by  LPIXEL



**COVID-19
pneumonia**

Ali-M3
by  Alibaba &  M3, Inc.



**Cerebral
aneurysm**

EIRL aneurysm
by  LPIXEL

 **New algorithms continue to onboard M3's AI platform**

Rapid Increase in AI Projects (1/2)

AI

			M3 Services					
			Medical Data Collection	Algorithm Development	Regulatory Consult	Clinical Study & Trial	Marketing Support	Funds
M3 Lead	M3	Respiratory	✓	✓	✓	✓	✓	✓
	M3	Diabetic Retinopathy	✓	✓	✓	✓	✓	✓
	M3	Osteoporosis	✓	✓	✓	✓	✓	✓
	M3	Medical institution (overseas)	✓	✓	✓	✓	✓	✓
	M3	COVID-19	✓	✓	✓	✓	✓	✓
	M3	Lung Cancer	✓	✓	✓			
M3 Support	Overseas	AI Venture					✓	
		AI Venture		✓				
		AI Venture		✓				
		AI Venture		✓				
		AI Venture			✓		✓	
		AI Venture	✓					
		AI Venture			✓	✓	✓	
		AI Venture			✓	✓	✓	
		AI Venture			✓	✓	✓	
		AI Venture			✓	✓	✓	
		AI Venture			✓	✓	✓	
		AI Venture			✓	✓	✓	
		AI Venture			✓	✓	✓	
		AI Venture			✓	✓	✓	
		Device Maker					✓	

Rapid Increase in AI Projects (2/2)

AI

		M3 Services					
		Medical Data Collection	Algorithm Development	Regulatory Consult	Clinical Study & Trial	Marketing Support	Funds
M3 Support	Domestic	AI Venture	Influenza	✓	✓		
		AI Venture	Unruptured Cerebral Aneurysm	✓			
		AI Venture	Insomnia	✓			✓
		Academia	Respiratory		✓		
		AI Venture	Gastrointestinal			✓	
		Device Maker	Fundoscopy			✓	
		Device Maker	Gastrointestinal Surgery	✓	✓		
		AI Venture	Alzheimers			✓	
		AI Venture	Fluoroscopic moving image		✓		
		AI Venture	Pathology			✓	
		AI Venture	Cardiovascular	✓	✓		
		Device Maker	PACS Connectivity			✓	
		Device Maker	Chest X-Ray & CT		✓		
		Device Maker	Endoscopy	✓	✓	✓	
		AI Venture	Endoscopy		✓		
		AI Venture	Head MRI, Chest X-Ray & CT, Mammography			✓	
		AI Venture	Cardiovascular	✓	✓		
		Device Maker	Chest CT			✓	
		Academia	Interstitial Pneumonia		✓		
		Device Maker	Head CT			✓	
		AI Venture	Report			✓	
		Device Maker	Endoscopy	✓			
		Device Maker	Head MRI, Gastro CT		✓	✓	✓

 45 cumulative AI projects to date. AI Platform launched.

COVID-19 Impact on M3 (Negative)

Q1 Assumptions

Q2 Assumptions

■ Clinical Trials (Evidence Solution)

- Temporary suspension in trial execution
- Potential for demand expansion from new R&D activity once conditions normalize
- **COVID-19 vaccine related trials expected to increase demand in the US**

Initiation of COVID-19 related vaccine trials supporting V-shaped recovery in the US clinical trial business

■ Stroke Rehabilitation (Medical Platform)

- Rehab center reduction in customers

■ Job Placements (Career Solution)

- Refrain from Job fairs, etc.

■ Hospital Management Support (Site Solution)

- Reduction in patients, changes in operational environment
- Reduction in home care nursing (especially rehab) patients

Less than expected demand depression, with cost reduction supporting solid results

Changes in Demand Type

Demand Loss

Negatives
(Temporary)



COVID-19 negative impact continues at a lesser pace than expected

US Clinical Trial Business Update

COVID-19 Related Trials

moderna

Vaccine



Vaccine



Vaccine*

REGENERON

Treatment

NOVAVAX

Vaccine



altimmune

Treatment

⋮


- COVID-19 related trial orders: several billion yen
- Current high pace expected to remain high for the fiscal year
- Further upside potential still exists




Post COVID-19 pipeline also healthy due to site and specialty area expansion

* (halted)

COVID-19 Impact on M3



Change in Growth Pace (start point: pre-COVID)



Short term neutral overall, structural changes expected to be largely positive for the mid to long term. Currently trending better than expected.

M3 Growth Strategy

Business Scope Expansion and Growth Potential


	2010	2014	2018	2022	
Country	: 3 →	5 (1.5x) →	10 (3x) →		
Business Types	: 6 →	10 (1.5x) →	26 (4x) →		Similar pace of growth expected over the next 4 years
Business Units (Type x Country)	: 10 →	18 (2x) →	41 (4x) →		
Sales (bn yen)	: 14.0 →	37.0 (2.5x) →	94.5 (7x) →		

 **Aggressive M&A to ensue in reaching growth potentials exceeding 10~20x current levels...**

Annual Results


Sales

(mn yen)



Operating Profit & Net Profit

(mn yen)



 **Forecasts were not given, however, growth is expected to continue on a fundamental basis, just as it had through events such as the Lehman shock and 311 earthquake in Japan**

* FY17 results retroactively restated according to IFRS9 (Financial Instruments)

Copyright © 2020 M3, Inc. All rights reserved.